\-\ Texto\\:\\ \ \(0\)\
\-\ bp\\ 99\\/60\\,\\ t\\ \\=\\ 101\\,\\ hr\\ 120\ \(0\)\
\-\ ua\\ \\+\\ leuk\\ est\\,\\ many\\ wbc\\,\\ many\\ bacteria\ \(0\)\
\-\ vauge\\ abd\\ and\\ flank\\ pain\\.\ \(1\)\
\-\ the\\ patient\\ received\\ antibiotics\\ and\\ recovered\\ well\\.\ \(0\)\
\-\ bilateral\\ striated\\ nephrograms\\,\\ l\\>r\\:\ \(0\)\
\-\ wedge\\ shaped\\ areas\\ of\\ decreased\\ enhancement\\ compared\\ to\\ normal\\ renal\\ parenchyma\\ with\\ associated\\ perinephric\\ fat\\ stranding\\ indicating\\ areas\\ of\\ edema\\ and\\ inflammation\\ in\\ the\\ kidneys\\.\ \(1\)\
\-\ pyelonephritis\ \(60\)\
\-\ \\â\\€\\¢\\ acute\\ pyelonephritis\ \(0\)\
\-\ \\â\\€\\¢\\ lobar\\ nephronia\ \(0\)\
\-\ \\â\\€\\¢\\ distal\\ obstruction\ \(0\)\
\-\ \\â\\€\\¢\\ tubular\\ obstruction\ \(0\)\
\-\ \\â\\€\\¢\\ trauma\\/contusion\ \(0\)\
\-\ \\â\\€\\¢\\ renal\\ vein\\ thrombosis\ \(0\)\
\-\ 21\\ yo\\ female\\ with\\ fever\\,\\ hypotension\\ and\\ flank\\ pain\\.\ \(0\)\
\-\ acute\\ pyelonephritis\\ is\\ caused\\ by\\ bacterial\\ infection\\ that\\ has\\ ascended\\ from\\ the\\ lower\\ urinary\\ tract\\ or\\,\\ \\ by\\ hematogenous\\ spread\\.\\ \\ antibiotics\\ typically\\ make\\ this\\ disease\\ easily\\ managed\\;\\ however\\,\\ complications\\ may\\ occur\\.\ \(0\)\
\-\ pyelonephritis\\ becomes\\ a\\ potentially\\ fatal\\ disease\\ when\\ secondary\\ conditions\\ develop\\,\\ such\\ as\\ emphysematous\\ pyelonephritis\\ \\(20\\-80\\%\\ mortality\\ rate\\)\\,\\ perinephric\\ abscess\\ \\(20\\-50\\%\\ mortality\\ rate\\)\\,\\ or\\ one\\ of\\ the\\ sepsis\\ syndromes\\ \\(\\>25\\%\\ overall\\ mortality\\ rate\\)\\.\\ \ \(0\)\
\-\ ct\\ is\\ generally\\ used\\ in\\ the\\ evaluation\\ of\\ pyelonephritis\\ to\\ asses\\ for\\ complications\\.\\ \\ long\\ term\\ complications\\ include\\ renal\\ scarring\\ and\\ potentially\\ decreased\\ renal\\ function\\ if\\ repetitive\\ infections\\ occur\\.\\ \\ the\\ most\\ common\\ pathogen\\ is\\ e\\.\\ coli\\ \\(70\\-80\\%\\)\\.\\ \\ others\\ include\\ enterococcus\\ faecalis\\,\\ klebsiella\\,\\ and\\ pseudomonas\\ aeruginosa\\.\\ \ \(0\)\
\-\ another\\ good\\ referrence\\ is\\:\ \(0\)\
\-\ \\"the\\ ct\\ nephrogram\\:\\ implications\\ for\\ evaluation\\ of\\ urinary\\ tract\\ disease\\"\\ \\ radiographics\\.\\ \\ 1995\\;\\ 15\\:1069\\-1085\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ pyelonephritis\\:\\ 0\\.11733828299946832\ \(0\)\
\-\ mortality\\:\\ 0\\.05478394518360972\ \(0\)\
\-\ perinephric\\:\\ 0\\.042465263076896805\ \(0\)\
\-\ renal\\:\\ 0\\.04027412626600893\ \(0\)\
\-\ complications\\:\\ 0\\.03983732700014185\ \(0\)\
\-\ potentially\\:\\ 0\\.03928514458193081\ \(0\)\
\-\ rate\\:\\ 0\\.039184958711480505\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.03687092591990324\ \(0\)\
\-\ 99\\/60\\:\\ 0\\.03457066048614313\ \(0\)\
\-\ nephronia\\:\\ 0\\.03457066048614313\ \(0\)\
\-\ trauma\\/contusion\\:\\ 0\\.03457066048614313\ \(0\)\
\-\ 20\\-80\\:\\ 0\\.03457066048614313\ \(0\)\
\-\ referrence\\:\\ 0\\.03457066048614313\ \(0\)\
\-\ nephrograms\\:\\ 0\\.03185243624865315\ \(0\)\
\-\ faecalis\\:\\ 0\\.03185243624865315\ \(0\)\
\-\ 15\\:1069\\-1085\\:\\ 0\\.03185243624865315\ \(0\)\
\-\ flank\\:\\ 0\\.03152727747740986\ \(0\)\
\-\ \\%\\:\\ 0\\.03126778091523149\ \(0\)\
\-\ urinary\\:\\ 0\\.031025145251802555\ \(0\)\
\-\ leuk\\:\\ 0\\.03026237700117015\ \(0\)\
\-\ vauge\\:\\ 0\\.03026237700117015\ \(0\)\
\-\ aeruginosa\\:\\ 0\\.03026237700117015\ \(0\)\
\-\ tract\\:\\ 0\\.029686905902541666\ \(0\)\
\-\ ascended\\:\\ 0\\.029134212011163167\ \(0\)\
\-\ enterococcus\\:\\ 0\\.029134212011163167\ \(0\)\
\-\ asses\\:\\ 0\\.028259139260911365\ \(0\)\
\-\ pathogen\\:\\ 0\\.028259139260911365\ \(0\)\
\-\ klebsiella\\:\\ 0\\.028259139260911365\ \(0\)\
\-\ pseudomonas\\:\\ 0\\.028259139260911365\ \(0\)\
\-\ many\\:\\ 0\\.027546772673783707\ \(0\)\
\-\ 70\\-80\\:\\ 0\\.027544152763680167\ \(0\)\
\-\ implications\\:\\ 0\\.026939640293769353\ \(0\)\
\-\ 20\\-50\\:\\ 0\\.026415987773673183\ \(0\)\
\-\ est\\:\\ 0\\.02595409351619717\ \(0\)\
\-\ antibiotics\\:\\ 0\\.02517424594251373\ \(0\)\
\-\ occur\\:\\ 0\\.02514546375514932\ \(0\)\
\-\ 101\\:\\ 0\\.024825928526190186\ \(0\)\
\-\ striated\\:\\ 0\\.024512035554921416\ \(0\)\
\-\ nephrogram\\:\\ 0\\.02422141605627937\ \(0\)\
\-\ obstruction\\:\\ 0\\.02363451018501518\ \(0\)\
\-\ 120\\:\\ 0\\.02302384096000023\ \(0\)\
\-\ coli\\:\\ 0\\.02302384096000023\ \(0\)\
\-\ fatal\\:\\ 0\\.022631356808796372\ \(0\)\
\-\ areas\\:\\ 0\\.022551742519576992\ \(0\)\
\-\ \\>\\:\\ 0\\.022267980507204427\ \(0\)\
\-\ repetitive\\:\\ 0\\.021793811317431435\ \(0\)\
\-\ hematogenous\\:\\ 0\\.02164581003122419\ \(0\)\
\-\ emphysematous\\:\\ 0\\.02150319181878939\ \(0\)\
\-\ wedge\\:\\ 0\\.02136557879992166\ \(0\)\
\-\ bacteria\\:\\ 0\\.021232631538448402\ \(0\)\
\-\ recovered\\:\\ 0\\.02074179568372681\ \(0\)\
\-\ 1995\\:\\ 0\\.02074179568372681\ \(0\)\
\-\ sepsis\\:\\ 0\\.020628119068537586\ \(0\)\
\-\ hypotension\\:\\ 0\\.020517645041217208\ \(0\)\
\-\ e\\.\\:\\ 0\\.020305616722510245\ \(0\)\
\-\ decreased\\:\\ 0\\.019927501197839682\ \(0\)\
\-\ others\\:\\ 0\\.019730701137444066\ \(0\)\
\-\ radiographics\\:\\ 0\\.019642572290965405\ \(0\)\
\-\ scarring\\:\\ 0\\.019556380499911385\ \(0\)\
\-\ evaluation\\:\\ 0\\.019468539575112218\ \(0\)\
\-\ lobar\\:\\ 0\\.019308620101395575\ \(0\)\
\-\ syndromes\\:\\ 0\\.01915173643624381\ \(0\)\
\-\ include\\:\\ 0\\.018801203827688524\ \(0\)\
\-\ easily\\:\\ 0\\.01851440730095842\ \(0\)\
\-\ managed\\:\\ 0\\.018023571446236827\ \(0\)\
\-\ make\\:\\ 0\\.017909894831047605\ \(0\)\
\-\ ua\\:\\ 0\\.017799420803727227\ \(0\)\
\-\ abd\\:\\ 0\\.017745329344384733\ \(0\)\
\-\ \\=\\:\\ 0\\.017587392485020264\ \(0\)\
\-\ becomes\\:\\ 0\\.017536129420050253\ \(0\)\
\-\ \\+\\:\\ 0\\.017289408536087236\ \(0\)\
\-\ indicating\\:\\ 0\\.017289408536087236\ \(0\)\
\-\ bacterial\\:\\ 0\\.017148498695985025\ \(0\)\
\-\ shaped\\:\\ 0\\.017057295314948685\ \(0\)\
\-\ develop\\:\\ 0\\.01671231973476846\ \(0\)\
\-\ conditions\\:\\ 0\\.016671255813720243\ \(0\)\
\-\ overall\\:\\ 0\\.016671255813720243\ \(0\)\
\-\ acute\\:\\ 0\\.016548073169462708\ \(0\)\
\-\ disease\\:\\ 0\\.016432206367243577\ \(0\)\
\-\ hr\\:\\ 0\\.016319835583564608\ \(0\)\
\-\ stranding\\:\\ 0\\.01620936155624423\ \(0\)\
\-\ spread\\:\\ 0\\.01620936155624423\ \(0\)\
\-\ \\'\\'\\:\\ 0\\.01615489805476269\ \(0\)\
\-\ infections\\:\\ 0\\.0159291303249417\ \(0\)\
\-\ \\;\\:\\ 0\\.015885656380020343\ \(0\)\
\-\ tubular\\:\\ 0\\.015604849086333413\ \(0\)\
\-\ received\\:\\ 0\\.015573848382383949\ \(0\)\
\-\ t\\:\\ 0\\.015512572625901278\ \(0\)\
\-\ kidneys\\:\\ 0\\.015422417652471087\ \(0\)\
\-\ term\\:\\ 0\\.015334288805992425\ \(0\)\
\-\ l\\:\\ 0\\.015276617639758325\ \(0\)\
\-\ r\\:\\ 0\\.015219782317003163\ \(0\)\
\-\ 21\\:\\ 0\\.015163758955248352\ \(0\)\
\-\ generally\\:\\ 0\\.015081196566237246\ \(0\)\
\-\ bp\\:\\ 0\\.014547344902219284\ \(0\)\
\-\ another\\:\\ 0\\.014407273990054266\ \(0\)\
\-\ thrombosis\\:\\ 0\\.014384407635894294\ \(0\)\
\-\ good\\:\\ 0\\.014339071077458703\ \(0\)\
\-\ parenchyma\\:\\ 0\\.01427203408389282\ \(0\)\
\-\ inflammation\\:\\ 0\\.01424994068107613\ \(0\)\
\-\ function\\:\\ 0\\.014206123815985442\ \(0\)\
\-\ compared\\:\\ 0\\.01418439761843401\ \(0\)\
\-\ caused\\:\\ 0\\.014056509047497692\ \(0\)\
\-\ \\,\\:\\ 0\\.013800905300881317\ \(0\)\
\-\ 25\\:\\ 0\\.013545985326498325\ \(0\)\
\-\ \\:\\:\\ 0\\.013297350776360765\ \(0\)\
\-\ used\\:\\ 0\\.012855624144893968\ \(0\)\
\-\ wbc\\:\\ 0\\.012215979806179654\ \(0\)\
\-\ vein\\:\\ 0\\.012125228713780852\ \(0\)\
\-\ typically\\:\\ 0\\.011829120664729303\ \(0\)\
\-\ long\\:\\ 0\\.011553809846402838\ \(0\)\
\-\ fever\\:\\ 0\\.01133828481000771\ \(0\)\
\-\ \\(\\:\\ 0\\.011331164333237028\ \(0\)\
\-\ \\)\\:\\ 0\\.011192748111581255\ \(0\)\
\-\ by\\:\\ 0\\.01115977179015588\ \(0\)\
\-\ abscess\\:\\ 0\\.01059543625150693\ \(0\)\
\-\ such\\:\\ 0\\.01047581486212099\ \(0\)\
\-\ fat\\:\\ 0\\.010191813030908365\ \(0\)\
\-\ yo\\:\\ 0\\.0100837314639324\ \(0\)\
\-\ infection\\:\\ 0\\.009741241466952185\ \(0\)\
\-\ when\\:\\ 0\\.009597377402415709\ \(0\)\
\-\ edema\\:\\ 0\\.0094781313311031\ \(0\)\
\-\ ct\\:\\ 0\\.009374930614839553\ \(0\)\
\-\ secondary\\:\\ 0\\.009368744966701205\ \(0\)\
\-\ however\\:\\ 0\\.009330855119988511\ \(0\)\
\-\ distal\\:\\ 0\\.00911089642723932\ \(0\)\
\-\ if\\:\\ 0\\.0090931115050221\ \(0\)\
\-\ one\\:\\ 0\\.009081299542394682\ \(0\)\
\-\ enhancement\\:\\ 0\\.008982308886757004\ \(0\)\
\-\ is\\:\\ 0\\.008820247504074128\ \(0\)\
\-\ common\\:\\ 0\\.008769675341005478\ \(0\)\
\-\ pain\\:\\ 0\\.008185162098280272\ \(0\)\
\-\ bilateral\\:\\ 0\\.008132618546331153\ \(0\)\
\-\ associated\\:\\ 0\\.007907696321206675\ \(0\)\
\-\ or\\:\\ 0\\.007855080384029078\ \(0\)\
\-\ most\\:\\ 0\\.007736608398933632\ \(0\)\
\-\ well\\:\\ 0\\.007580709619484906\ \(0\)\
\-\ lower\\:\\ 0\\.0075367139975053435\ \(0\)\
\-\ may\\:\\ 0\\.00735030732901225\ \(0\)\
\-\ female\\:\\ 0\\.006889255966462093\ \(0\)\
\-\ has\\:\\ 0\\.0062929410607618745\ \(0\)\
\-\ that\\:\\ 0\\.005788159719838523\ \(0\)\
\-\ for\\:\\ 0\\.005718495283472276\ \(0\)\
\-\ normal\\:\\ 0\\.005253382174898435\ \(0\)\
\-\ as\\:\\ 0\\.005068931395663247\ \(0\)\
\-\ from\\:\\ 0\\.004966414561389068\ \(0\)\
\-\ and\\:\\ 0\\.004235506017228669\ \(0\)\
\-\ the\\:\\ 0\\.0037950784036289435\ \(0\)\
\-\ this\\:\\ 0\\.003769165542408365\ \(0\)\
\-\ patient\\:\\ 0\\.0033591840428093644\ \(0\)\
\-\ to\\:\\ 0\\.003349553791709696\ \(0\)\
\-\ in\\:\\ 0\\.003305076314825529\ \(0\)\
\-\ of\\:\\ 0\\.0022843882509409495\ \(0\)\
\-\ \\.\\:\\ 0\\.001809780271629418\ \(0\)\
\-\ a\\:\\ 0\\.001555293340465103\ \(0\)\
\-\ with\\:\\ 0\\.0009176798124697234\ \(0\)\
